FDA Determines Regulatory Review Period for MYOVIEW Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for MYOVIEW, a human drug product, as required by law, following a submission to the Commissioner of Patents and Trademarks for patent extension.